OPRD1 (Delta-Opioid Receptor, DOR) encodes a G protein-coupled receptor (GPCR) that plays crucial roles in pain modulation, emotional processing, motor control, and neuroprotection. The delta-opioid receptor has emerged as a significant therapeutic target in neurodegenerative diseases, particularly Alzheimer's Disease (AD) and Parkinson's Disease (PD), due to its neuroprotective properties against excitotoxicity, oxidative stress, and protein aggregation.
| Symbol | OPRD1 |
|---|
| Full Name | Delta-Opioid Receptor (DOR) |
|---|
| Chromosomal Location | 1p36.12 |
|---|
| NCBI Gene ID | [4981](https://www.ncbi.nlm.nih.gov/gene/4981) |
|---|
| OMIM | [165070](https://www.omim.org/entry/165070) |
|---|
| Ensembl ID | [ENSG00000116381](https://www.ensembl.org/Human/Gene/Summary?g=ENSG00000116381) |
|---|
| UniProt | [P41143](https://www.uniprot.org/uniprot/P41143) |
|---|
¶ Protein Structure and Function
The delta-opioid receptor is a 372-amino acid GPCR characterized by:
- Seven transmembrane helices (TM1-TM7)
- Extracellular N-terminus with glycosylation sites
- Intracellular C-terminus involved in G protein coupling
- Conserved DRYLAIV motif in TM3 for G protein activation
OPRD1 couples to multiple G protein subtypes, activating diverse signaling cascades:
Gαi/o-dependent pathways:
- Inhibition of adenylyl cyclase → reduced cAMP
- Activation of inward rectifier K+ channels (GIRK)
- Modulation of voltage-gated calcium channels
- Activation of MAPK pathways (ERK1/2, JNK, p38)
β-arrestin pathways:
- Receptor internalization and recycling
- Activation of PI3K/Akt survival signaling
- MAPK cascade modulation
OPRD1 exhibits region-specific expression throughout the central nervous system:
Delta-opioid receptor activation provides neuroprotection against amyloid-beta (Aβ) toxicity through multiple mechanisms [@chen2020]:
- Reduction of Aβ-induced ROS: DOR agonists attenuate oxidative stress generated by Aβ accumulation
- Inhibition of apoptotic pathways: Activation blocks caspase-3 activation and DNA fragmentation
- Modulation of tau phosphorylation: DOR signaling influences GSK-3β activity, reducing tau pathology [@guerrero2018]
- Preservation of synaptic function: DOR activation maintains dendritic spine density and synaptic plasticity
OPRD1 plays a critical role in regulating neuroinflammatory responses in AD [@gadd2021]:
- Microglial activation: DOR agonists reduce pro-inflammatory cytokine release (IL-1β, TNF-α, IL-6)
- Astrocyte function: Modulation of astrocytic reactivity and gliosis
- NF-κB pathway: Inhibition of nuclear factor kappa-B signaling
- COX-2 regulation: Reduced cyclooxygenase-2 expression
The cholinergic system, severely affected in AD, interacts with OPRD1 signaling:
- Cholinergic neurons express DOR and respond to delta-opioid ligands
- DOR agonism protects basal forebrain cholinergic neurons
- Potential for combination therapy with acetylcholinesterase inhibitors
Postmortem studies of AD brain tissue reveal altered OPRD1 expression [@fabbri2020]:
- Reduced DOR density in the hippocampus and cortex
- Correlation between receptor loss and cognitive decline
- PET imaging with selective DOR ligands shows reduced binding in AD patients [@stoppelbein2022]
The substantia nigra pars compacta (SNc) expresses high levels of OPRD1, making it a therapeutic target for PD [@su2008]:
- Mitochondrial protection: DOR agonists preserve mitochondrial membrane potential and reduce ROS [@li2019]
- Autophagy regulation: DOR activation enhances clearance of damaged mitochondria and α-synuclein [@liu2020]
- Anti-apoptotic effects: Blockade of mitochondrial apoptosis pathway
- Inflammation reduction: Modulation of microglial activation in the SNc
Delta-opioid receptor activation protects against α-synuclein-induced neurodegeneration [@hua2020]:
- Reduced α-synuclein aggregation
- Enhanced lysosomal degradation of α-synuclein
- Preservation of dopaminergic neuron viability
Postmortem studies demonstrate OPRD1 alterations in PD [@valentini2012]:
- Increased DOR binding in the striatum of PD patients
- Correlation with disease severity
- Potential compensatory upregulation
¶ Lewy Body Dementia
OPRD1 is also implicated in Dementia with Lewy Bodies (DLB) [@catchlove2022]:
- Altered opioid receptor density in DLB brain
- Relationship to motor and non-motor symptoms
- PET imaging potential for differential diagnosis
Several delta-opioid receptor agonists have been investigated for neuroprotection:
| Compound |
Status |
Primary Target |
Notes |
| DPDPE |
Research |
DOR |
First selective DOR agonist |
| DADLE |
Research |
DOR |
Metabolically stable |
| SNC-80 |
Research |
DOR |
Blood-brain barrier permeable |
| ARM390 |
Research |
DOR |
Biased agonist |
Potential benefits:
- Neuroprotection without addictive properties
- Oral bioavailability with appropriate compounds
- Combination potential with existing therapies
Challenges:
- Seizure risk at high doses
- Tolerance development
- Peripheral side effects
OPRD1-targeted approaches may combine with:
Delta-opioid receptor activation provides robust protection against excitotoxic cell death [@meng2019]:
- Reduced calcium influx through voltage-gated channels
- Enhanced potassium conductance
- Preserved mitochondrial function
- Reduced caspase activation
- DOR activation indirectly modulates NMDA receptor activity
- Reduces glutamate-induced calcium overload
- Protects against excitotoxic cascades
¶ Autophagy and Protein Clearance
OPRD1 signaling regulates autophagy, critical for clearing toxic protein aggregates [@liu2020]:
- mTOR inhibition: DOR agonists suppress mTORC1 activity
- LC3 conversion: Enhanced lipidation of LC3
- Lysosomal function: Improved lysosomal degradation capacity
- Aggregate clearance: Reduced protein aggregate burden
OPRD1 genetic variants have been associated with:
- Susceptibility to Alzheimer's disease
- Response to opioid analgesics
- Age of onset in Parkinson's disease
- Cognitive decline progression
- Interactions with environmental neurotoxins
- Modulation of pesticide exposure risk
- Response to pharmacotherapy
Development of selective DOR PET ligands enables:
- In vivo visualization of receptor density
- Disease progression monitoring
- Therapeutic response assessment
Biased DOR agonists that favor β-arrestin signaling offer:
- Enhanced neuroprotection
- Reduced side effects
- Improved therapeutic windows
Viral vector delivery of OPRD1:
- Sustained receptor expression
- Targeted delivery to affected brain regions
- Potential disease modification
The regional distribution of OPRD1 in the brain has been extensively characterized through postmortem studies, PET imaging, and animal models:
High Expression Regions:
- Striatum: Highest density in the dorsal striatum (caudate nucleus and putamen), involved in motor control and habit formation
- Nucleus Accumbens: Core and shell regions, critical for reward and motivation
- Periaqueductal Gray (PAG): Major site of endogenous opioid analgesia
- Thalamus: Moderate to high expression, particularly in the medial nuclei
Moderate Expression Regions:
- Hippocampus: CA1-CA3 regions and dentate gyrus; higher in the stratum radiatum and molecular layer
- Cortex: Layer-specific distribution, highest in layers II-III and V
- Amygdala: Particularly in the basolateral complex
- Substantia Nigra: Pars compacta dopaminergic neurons express DOR
- Ventral Tegmental Area (VTA): Dopaminergic neurons
Lower Expression Regions:
- Cerebellum: Primarily in the granular layer
- Hypothalamus: Moderate expression in the arcuate nucleus
- Brainstem: Varying expression across nuclei
The differential distribution of OPRD1 across brain regions explains its diverse roles in motor control, reward processing, pain modulation, and cognitive function, all of which are affected in neurodegenerative diseases.
¶ Aging and OPRD1
The aging brain shows significant alterations in OPRD1 expression and function [@dietl2015]:
- Receptor density reduction: 30-40% decrease in DOR binding in the aged brain
- G protein coupling efficiency: Reduced efficacy of second messenger signaling
- Signal transduction deficits: Impaired downstream kinase activation
- Regional vulnerability: Hippocampus and cortex show greatest age-related decline
These changes may contribute to age-related cognitive decline and increased susceptibility to neurodegenerative diseases.
Age-associated OPRD1 dysfunction involves:
- Oxidative damage: Accumulated ROS affects receptor structure and function
- Glycosylation changes: Altered post-translational processing
- Membrane lipid composition: Changes in receptor microdomain localization
- Epigenetic regulation: Altered promoter methylation and histone modifications
OPRD1 plays important roles in modulating synaptic plasticity [@chen2018]:
Long-Term Potentiation (LTP):
- DOR activation enhances LTP in the hippocampus
- Mechanisms involve NMDA receptor modulation
-ERK/MAPK pathway activation
- Calcium handling improvements
Long-Term Depression (LTD):
- DOR agonism facilitates LTD induction
- GABAergic modulation involved
- AMPA receptor internalization
DOR functions as a presynaptic receptor modulating neurotransmitter release:
- Glutamate release: Inhibition of vesicular glutamate release
- GABA release: Reduced inhibitory transmission
- Dopamine release: Modulation in striatum and VTA
- Acetylcholine release: Cholinergic neuron regulation
OPRD1 signaling modulates multiple ion channels:
- Voltage-gated calcium channels: N-type and P/Q-type inhibition
- Potassium channels: GIRK channel activation
- Sodium channels: Modulation of sodium currents
- TRPV1: Cross-talk with capsaicin receptors
Several preclinical models have informed understanding of OPRD1 in neurodegeneration:
- OPRD1 knockout mice: Show increased vulnerability to MPTP toxicity
- Transgenic DOR overexpression: Protected against Aβ toxicity
- Conditional knockout models: Region-specific deletion studies
- Knock-in models: Point mutations affecting G protein coupling
- Primary neuronal cultures: Acute DOR agonist treatment
- Organotypic slice cultures: Long-term exposure studies
- iPSC-derived neurons: Patient-specific models
- Microglial cultures: Inflammation modulation studies
OPRD1 PET ligands serve as biomarkers:
| Ligand |
Target |
Clinical Use |
| [^11C]DPDPE |
DOR |
Receptor occupancy |
| [^18F]DUPK |
DOR |
Imaging studies |
| [^11C]GR103545 |
DOR |
High affinity |
Key considerations for clinical development:
- Dose optimization: Neuroprotective vs. analgesic doses differ
- Temporal window: Early intervention may be more effective
- Combination approaches: Synergistic with other neuroprotectants
The delta-opioid receptor activates multiple intracellular signaling pathways critical for neuroprotection [@tian2014]:
Primary Pathways:
-
Adenylyl Cyclase Inhibition
- Gαi/o protein inhibits AC activity
- Reduced cAMP accumulation
- PKA activity modulation
- CREB phosphorylation alterations
-
MAPK/ERK Cascade
- Ras activation via β-arrestin
- Raf-1 → MEK → ERK phosphorylation
- Nuclear translocation of ERK
- Gene expression regulation
-
PI3K/Akt Pathway
- β-arrestin-dependent PI3K activation
- Akt phosphorylation at Ser473
- mTORC1 regulation
- Bad phosphorylation (anti-apoptotic)
-
PLC/Ca²⁺ Signaling
- Gβγ subunits activate PLCβ
- IP₃ and DAG production
- Intracellular calcium release
- PKC activation
Cross-talk Mechanisms:
- cAMP-PKA interaction: Bidirectional modulation
- MAPK-PI3K crosstalk: Parallel survival signaling
- PKC cross-activation: Multiple kinase pathways
- Calcium-dependent proteases: Calpain regulation
OPRD1 expression is epigenetically regulated:
- DNA methylation: Promoter methylation inversely correlates with expression
- Histone modifications: Acetylation at H3K9 enhances expression
- miRNA regulation: miR-339 and miR-212 target OPRD1 mRNA
- lncRNA interactions: Regulatory RNA-mediated control
OPRD1 activation significantly modulates microglial function [@xu2016]:
Anti-inflammatory Effects:
- Reduced IL-1β, TNF-α, and IL-6 release
- Increased IL-10 production
- Suppressed COX-2 and iNOS expression
- NF-κB pathway inhibition
Morphological Changes:
- Reduced microglial ramification
- Decreased pro-inflammatory phenotypes
- Enhanced surveillance mode
Phagocytic Function:
- Modulated phagocytosis of debris
- Enhanced clearance of Aβ aggregates
- Improved neuronal debris removal
Astrocytes express OPRD1 and respond to agonist stimulation:
- Reactive astrocytosis modulation: ReducedGFAP expression
- Glutamate uptake enhancement: Improved excitotoxicity protection
- Potassium buffering: Regulated K⁺ homeostasis
- Metabolic support: Enhanced lactate provision to neurons
OPRD1 agonists protect mitochondrial function through multiple mechanisms [@zhang2021]:
Mitochondrial Biogenesis:
- PGC-1α activation
- Increased mitochondrial DNA copy number
- Enhanced respiratory chain complex expression
Fission/Fusion Balance:
- Reduced excessive fission (Drp1 inhibition)
- Enhanced fusion (Mfn1/2, OPA1)
- Balanced dynamics maintenance
mtDNA Protection:
- Reduced oxidative damage to mtDNA
- Enhanced repair mechanisms
- Improved mitochondrial protein synthesis
- ATP production: Maintained cellular energy levels
- Membrane potential: Preserved ΔΨm
- Respiratory control: Maintained coupling efficiency
- Substrate utilization: Enhanced glucose metabolism
¶ Learning and Memory
OPRD1 plays important roles in cognitive processes [@chen2018]:
Memory Formation:
- Enhanced consolidation through DOR activation
- Improved retrieval in contextual memory tasks
- Spatial memory preservation
Working Memory:
- Prefrontal cortex DOR involvement
- Optimal arousal modulation
- Attention regulation
OPRD1 modulates prefrontal cortical excitability [@hou2017]:
- Neuronal firing patterns: Regulated action potential generation
- Synaptic integration: Improved dendritic integration
- Network oscillations: Modulated gamma and theta rhythms
- Executive function: Enhanced cognitive flexibility
¶ Preclinical Candidates
| Agent |
Mechanism |
Stage |
Indication |
| DPDPE |
Full agonist |
Preclinical |
PD model |
| DADLE |
Full agonist |
Preclinical |
AD model |
| TAN-67 |
Agonist |
Preclinical |
Stroke |
| SB-205607 |
Partial agonist |
Preclinical |
TBI |
| ODM-116 |
Biased agonist |
Lead optimization |
PD |
¶ Clinical Candidates
Currently, no DOR-targeted neuroprotective drugs are in clinical trials for neurodegenerative diseases. However:
- Repurposing potential: Existing DOR agonists for analgesia
- Formulation advantages: BBB-penetrant compounds available
- Safety profile: Established human safety data
¶ Challenges and Solutions
Challenges:
- Seizure risk: Dose-limiting toxicity
- Tolerance: Long-term efficacy concerns
- Peripheral effects: Nausea, constipation
Solutions:
- Biased agonism: β-arrestin bias reduces seizures
- Peripheral restriction: Limited BBB penetration
- Combination therapy: Lower doses with synergy
OPRD1 belongs to the opioid receptor family with distinct functions:
| Receptor |
Gene |
Primary Function |
Neuroprotection |
| μ (MOR) |
OPRM1 |
Analgesia |
Moderate |
| δ (DOR) |
OPRD1 |
Neuroprotection |
Strong |
| κ (KOR) |
OPRK1 |
Dysphoria |
Variable |
| NOP |
OPRL1 |
Reward modulation |
Mixed |
- Phylogenetic history: Ancient receptor family
- Species conservation: High conservation across mammals
- Functional conservation: Similar signaling across species
- Isoform diversity: Multiple splice variants
- Radioligand binding: [^3H]DPDPE, [^125I]DPDPE
- Immunohistochemistry: DOR-specific antibodies
- In situ hybridization: mRNA localization
- PET imaging: [^11C]DPDPE, [^18F]fluoroethyl-DPDPE
- Functional assays: GTPγS binding
- In vitro: Cell lines, primary neurons, organotypic cultures
- In vivo: Mouse, rat, non-human primate models
- Computational: Docking studies, molecular dynamics
- Clinical: PET studies, postmortem analysis
- Mechanism specificity: Which signaling pathway is most important for neuroprotection?
- Temporal window: When is DOR-targeted intervention most effective?
- Disease-specific effects: Are there optimal indications?
- Combination strategies: What are the best combination partners?
- Single-cell RNAseq: OPRD1 expression heterogeneity
- Optogenetics: Light-controlled DOR signaling
- Chemogenetics: DREADD-based approaches
- Gene editing: CRISPR-based OPRD1 modulation
¶ Proteins and Pathways
- Gadd et al., delta-Opioid receptor activation attenuates neuroinflammation in Alzheimer's disease (2021)
- Chen et al., Neuroprotective effects of delta-opioid receptor agonists against beta-amyloid toxicity (2020)
- Narita et al., Implications of delta-opioid receptor systems in Alzheimer's disease (2006)
- Su et al., Deletion of the delta opioid receptor gene in mice impairs nigrostriatal dopamine function (2008)
- Valentini et al., Opioid receptors in Parkinson's disease: a postmortem study (2012)
- Browne et al., The delta-opioid receptor as a therapeutic target for Parkinson's disease (2013)
- Hua et al., delta-Opioid receptor activation protects dopaminergic neurons from alpha-synuclein toxicity (2020)
- Catchlove et al., Opioid receptor density in the brains of patients with dementia with Lewy bodies (2022)
- Meng et al., Activation of delta-opioid receptors reduces excitotoxicity in cortical neurons (2019)
- Guerrero et al., delta-Opioid receptor modulates tau phosphorylation and aggregation (2018)
- Li et al., delta-Opioid receptor agonist protects against mitochondrial dysfunction in Parkinson's models (2019)
- Yang et al., Targeting delta-opioid receptors for the treatment of Alzheimer's disease (2018)
- Stoppelbein et al., PET imaging of delta-opioid receptors in neurodegenerative diseases (2022)
- Fabbri et al., Dysregulation of opioid system in Alzheimer's disease brain (2020)
- Fan et al., delta-Opioid receptor signaling in neuroinflammation in Alzheimer's disease (2021)
- Liu et al., delta-Opioid receptors and autophagy in models of Parkinson's disease (2020)
- Dietl et al., Opioid receptors in the aged brain (2015)
- Tian et al., Molecular mechanisms of delta-opioid receptor-mediated neuroprotection (2014)
- Xu et al., Activation of delta-opioid receptors prevents amyloid-beta-induced astrogliosis (2016)
- Zhang et al., delta-Opioid receptor agonist attenuates mitochondrial fission in MPTP model of Parkinson's disease (2021)
- Wang et al., Targeting delta-opioid receptor for the treatment of neuropsychiatric disorders (2017)
- Chen et al., The role of delta-opioid receptors in learning and memory (2018)
- Hou et al., delta-Opioid receptors modulate neuronal excitability in the prefrontal cortex (2017)